Bookmark and Share

$POAI Exclusive Resources Provide Personal Profiling, Tools to Improve Patient Outcomes

  • POAI, Helomics builds AI-driven models that predict drug response, patient outcome
  • Company tests patient tumor, generates comprehensive picture that oncologists use to individualize therapy
  • Key to individualized insight is POAI’s Tumor Drug Response Profiling (“TDRP”) platform, NGS-based genomic profiling, unmatched cancer knowledge base

Guided by the mantra that “cancer is personal — we believe therapy should be too,” Predictive Oncology (NASDAQ: POAI) subsidiary Helomics focus on building AI-driven models that will predict drug response and patient outcome of individual tumors. With the largest tumor inventory in the world, POAI leads the way in providing a functional precision medicine approach that harnesses the power of an individual patient’s tumor to personalize their cancer treatment plan.

POAI works closely with oncologists to provide key information to help improve their patients’ odds in their fight against cancer. Helomics current clinical test platform offers a powerful, proprietary approach that tests a patient’s unique tumor, then combines drug-response profiling and genomic profiling of that tumor to generate a comprehensive picture that an oncologist can use to individualize therapy and improve positive outcomes.

Oncologists rely on these personalized profiles to help reduce the risk that a patient receives ineffective therapies as well as to identify alternatives when a typical treatment recommended for certain types of cancer cannot be tolerated.

A key component in Predictive Oncology’s ability to offer such individualized insight is the company’s Tumor Drug Response Profiling (“TDRP”) platform, which it combines with the latest NGS-based genomic profiling and POAI’s vast cancer knowledge-base of 150,000 tumors. Exclusive to POAI, these resources provide a more functional approach to precision medicine and allow an oncologist to reach beyond genomics alone in providing cancer-treatment recommendations.

In addition, every tumor tested by POAI and Helomics adds data to the company’s unparalleled D-CHIP knowledgebase, which contains anonymized molecular and drug-response profiles from more than 150,000 cancer cases. This invaluable information provides researchers in pharma, biopharma and diagnostic companies actionable insights to help discover better targeted therapies as well as contribute to key developments in clinical trials, companion diagnostics, and biomarkers.

POAI is bringing precision medicine, or tailored medical treatment using the individual characteristics of each patient, to the treatment of cancer. Through the company’s Helomics division, the company leverages its unique, clinically validated patient derived (“PDx”) smart tumor profiling platform to provide oncologists with a road map to help individualize therapy. In addition, the company is utilizing artificial intelligence and its proprietary database of over 150,000 cancer cases tumors to build AI-driven models of tumor drug response to improve outcomes for the patients of today and tomorrow

For more information about the company, visit

NOTE TO INVESTORS: The latest news and updates relating to POAI are available in the company’s newsroom at

About BioMedWire

BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published:

BioMedWire (BMW)
San Francisco, California
415.949.5050 Office

BioMedWire is part of the InvestorBrandNetwork.

Wednesday, August 26th, 2020 Uncategorized
Top Small Cap Market News